Elevation Oncology (ELEV) Competitors $0.38 0.00 (-0.45%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.38 +0.00 (+0.56%) As of 07/11/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELEV vs. CRBP, CLLS, ORMP, CHRS, MGNX, ZNTL, ELUT, TCRX, EXOZ, and CLYMShould you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Corbus Pharmaceuticals (CRBP), Cellectis (CLLS), Oramed Pharmaceuticals (ORMP), Coherus Oncology (CHRS), MacroGenics (MGNX), Zentalis Pharmaceuticals (ZNTL), Elutia (ELUT), TScan Therapeutics (TCRX), eXoZymes (EXOZ), and Climb Bio (CLYM). These companies are all part of the "pharmaceutical products" industry. Elevation Oncology vs. Its Competitors Corbus Pharmaceuticals Cellectis Oramed Pharmaceuticals Coherus Oncology MacroGenics Zentalis Pharmaceuticals Elutia TScan Therapeutics eXoZymes Climb Bio Corbus Pharmaceuticals (NASDAQ:CRBP) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment. Which has higher earnings & valuation, CRBP or ELEV? Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Elevation Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorbus PharmaceuticalsN/AN/A-$40.21M-$4.22-1.96Elevation OncologyN/AN/A-$44.49M-$0.82-0.46 Do institutionals & insiders believe in CRBP or ELEV? 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are held by institutional investors. 3.6% of Corbus Pharmaceuticals shares are held by insiders. Comparatively, 8.1% of Elevation Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is CRBP or ELEV more profitable? Corbus Pharmaceuticals' return on equity of -36.87% beat Elevation Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Corbus PharmaceuticalsN/A -36.87% -32.87% Elevation Oncology N/A -74.68%-48.14% Does the media favor CRBP or ELEV? In the previous week, Corbus Pharmaceuticals and Corbus Pharmaceuticals both had 2 articles in the media. Corbus Pharmaceuticals' average media sentiment score of 1.71 beat Elevation Oncology's score of 0.32 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Elevation Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer CRBP or ELEV? Corbus Pharmaceuticals currently has a consensus target price of $50.88, indicating a potential upside of 515.18%. Elevation Oncology has a consensus target price of $3.39, indicating a potential upside of 798.31%. Given Elevation Oncology's higher probable upside, analysts plainly believe Elevation Oncology is more favorable than Corbus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corbus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Elevation Oncology 0 Sell rating(s) 11 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility & risk, CRBP or ELEV? Corbus Pharmaceuticals has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. SummaryCorbus Pharmaceuticals beats Elevation Oncology on 8 of the 13 factors compared between the two stocks. Get Elevation Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELEV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELEV vs. The Competition Export to ExcelMetricElevation OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.32M$2.94B$5.56B$9.11BDividend YieldN/A2.42%5.06%4.01%P/E Ratio-0.4620.8528.2320.27Price / SalesN/A298.79434.20100.92Price / CashN/A42.1137.1257.67Price / Book0.377.638.045.49Net Income-$44.49M-$55.05M$3.19B$250.45M7 Day Performance-2.10%8.43%3.62%4.78%1 Month Performance-1.26%8.14%5.98%9.58%1 Year Performance-86.91%1.62%29.39%16.41% Elevation Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELEVElevation Oncology2.8576 of 5 stars$0.38-0.4%$3.39+798.3%-86.9%$22.32MN/A-0.4640CRBPCorbus Pharmaceuticals4.4789 of 5 stars$7.30-5.3%$50.88+596.9%-86.0%$89.35MN/A-1.7340Positive NewsCLLSCellectis3.4337 of 5 stars$1.60+1.3%$4.00+150.0%-23.9%$88.93M$49.22M-1.86290ORMPOramed Pharmaceuticals1.0445 of 5 stars$2.16-0.9%N/A-15.5%$88.24M$1.34M-4.9110Positive NewsCHRSCoherus Oncology3.7968 of 5 stars$0.75-7.9%$4.68+527.6%-47.0%$86.51M$266.96M-0.66330News CoverageMGNXMacroGenics4.2543 of 5 stars$1.36-6.8%$5.71+320.2%-65.7%$85.80M$149.96M-1.53430News CoverageAnalyst UpgradeZNTLZentalis Pharmaceuticals2.2206 of 5 stars$1.19-5.6%$8.37+603.1%-66.5%$85.62M$26.87M-0.38160News CoverageELUTElutia3.4404 of 5 stars$2.08-0.5%$8.00+284.6%-45.7%$85.53M$24.38M-1.08180TCRXTScan Therapeutics3.6067 of 5 stars$1.45-4.0%$7.80+437.9%-73.1%$85.45M$4.42M-1.33100News CoverageAnalyst UpgradeEXOZeXoZymesN/A$10.18+2.7%N/AN/A$85.21M$70K0.0029Positive NewsGap DownCLYMClimb Bio3.5148 of 5 stars$1.26-1.6%$9.00+614.3%N/A$85.15MN/A-0.539News CoverageGap Up Related Companies and Tools Related Companies CRBP Alternatives CLLS Alternatives ORMP Alternatives CHRS Alternatives MGNX Alternatives ZNTL Alternatives ELUT Alternatives TCRX Alternatives EXOZ Alternatives CLYM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELEV) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevation Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevation Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELEV Stock Alerts